Menu Back to Oligonucleotide-Based-Therapeutics-Conference

Overview

Conference: April 25-27

DIA is offering both a live in-person conference or an On Demand Library for the DIA/FDA Oligonucleotide-Based Therapeutics Conference that allows you to view all the session recordings from the comfort of your own home/office at your own pace. Upon registration, please indicate via the check box which avenue you are registering for: in-person or on demand.

Co-sponsored with FDA!

DIA Virtual Conference

DIA/FDA's Oligonucleotide-based Therapeutics Conference brings together leading experts to inform, educate, and share advancements in oligonucleotide-based therapeutic product development. Developed collaboratively by regulators, industry professionals, and academics, the program covers a wide range of topics from the nonclinical, CMC, and clinical areas. The conference offers a unique experience with multiple perspectives presented, and the opportunity to interface with regulators from around the globe.

Social distancing measures may be in place at the time of the event. Therefore, we encourage you to register and make your housing arrangements early due to potential limited capacity. If the capacity limit is reached, we will only be able to offer the virtual option. Don’t miss out on your chance to meet live again with your friends and colleagues!

We are thrilled to able to offer flexibility to our attendees to attend in-person or later in a self-paced On Demand format. Please note, we are also offering flexibility to our speakers so you will experience some speakers presenting in-person and others remotely.

Who should attend?

Senior-level professionals and those working in the following areas of oligonucleotide science:
  • Drug Discovery
  • Preclinical
  • Clinical
  • CMC
  • Quality Assurance
  • RNAi
  • Vaccines
  • Biotechnology
  • Delivery Technologies
  • Clinical Pharmacology/Research

Learning objectives

At the conclusion of this activity, participants should be able to:
  • Analyze the latest strategies for clinical use of oligonucleotide therapies
  • Describe the chemistry, manufacturing, and controls challenges associated with the development of oligonucleotides, including formulation and specification issues
  • Explain the latest global regulatory updates in oligonucleotide therapeutic developments
  • Evaluate the best mechanism of interactions with patients and partner organizations to address critical needs in the rare disease community

Program Committee

  • Benjamin  Stevens, PhD, MPH
    Benjamin Stevens, PhD, MPH Director CMC Policy and Advocacy
    GlaxoSmithKline, United States
  • Scott  Henry, PhD
    Scott Henry, PhD Vice President, Nonclinical Development
    Ionis Pharmaceuticals, Inc., United States
  • Ronald L. Wange, PhD
    Ronald L. Wange, PhD Associate Director for Pharm/Tox ODE3, CDER
    FDA, Office of New Drugs, United States
  • Louis  O'Dea, MD
    Louis O'Dea, MD Executive Vice President, Chief Medical Officer and Head, Regulatory Affairs
    Akcea Therapeutics, United States
  • Hobart  Rogers, PharmD, PhD
    Hobart Rogers, PharmD, PhD Pharmacologist
    FDA, United States
  • Laura  Sepp-Lorenzino, PhD
    Laura Sepp-Lorenzino, PhD Chief Scientific Officer
    Intellia Therapeutics, Inc., United States
  • Andrew  Slugg, MBA, MS
    Andrew Slugg, MBA, MS VP, Regulatory Affairs
    Alnylam Pharmaceuticals, United States
  • Barry  Ticho, DrMed, PhD
    Barry Ticho, DrMed, PhD Chief Medical Officer
    Stoke Therapeutics, United States
  • Daniel  Capaldi, PhD
    Daniel Capaldi, PhD Vice President, Analytical and Process Development
    Ionis Pharmaceuticals, Inc., United States
  • Monica  Cooper, PhD
    Monica Cooper, PhD Review Chemist
    FDA, United States
  • Kim  Tyndall
    Kim Tyndall President
    CMC Tyndall Consultant LLC, United States
  • Ramin  Darvari, PhD, MS
    Ramin Darvari, PhD, MS Associate Research Fellow
    Pfizer Inc., United States
  • Ramesh  Raghavachari, PhD
    Ramesh Raghavachari, PhD Chief, Branch I, DPMA1, OLDP, OPQ, CDER
    FDA, United States
  • Susan  Srivasta, PhD
    Susan Srivasta, PhD President
    ElixinPharma, United States
  • René  Thürmer, PhD
    René Thürmer, PhD Deputy Head of the Unit Pharmaceutical Biotechnology BfArM
    Federal Institute for Drugs and Medical Devices, Germany
  • Patrik  Andersson, PhD
    Patrik Andersson, PhD Principal Scientist, Discovery Safety Specialist
    AstraZeneca R&D, Sweden
  • Fran  Wincott, PhD
    Fran Wincott, PhD President
    Wincott & Associates LLC, United States
  • Elena  Braithwaite, PhD
    Elena Braithwaite, PhD Toxicologist
    FDA, United States
  • Xuan  Chi, MD, PhD
    Xuan Chi, MD, PhD Pharmacologist/Acting Team Leader
    CDER, FDA, United States
  • David  Corey, PhD
    David Corey, PhD Professor
    UT Southwestern Medical Center at Dallas, United States
  • Jeffrey  Foy, PhD
    Jeffrey Foy, PhD Senior Director of Toxicology
    Dicerna Pharmaceuticals, United States
  • Aimee L. Jackson, PhD
    Aimee L. Jackson, PhD Chief Scientific Officer
    Atalanta Therapeutics, United States
  • Arthur A. Levin, PhD
    Arthur A. Levin, PhD Executive Vice President, Research and Development
    Avidity Biosciences , United States
  • Emily J. Place, PhD, MPH
    Emily J. Place, PhD, MPH Pharmacologist, Office of New Drugs, CDER
    FDA, United States
Load More

Digital Learning Catalog

DIA Learning: eLearning Soultions
Download